lung cancer, esophageal cancer, gastric cancer, biliary tract cancer, pancreatic cancer, colorectal cancer
Conditions
Interventions
None listed
Sponsors
Clinical Research Center, Saga University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20 years old or older at written informed consent. 2. Patients have a confirmed diagnosis of cancer and the primary site of cancer is following: lung, pancreas, biliary tract, stomach, esophagus, colorectum (both initial and/or recurrence). Except active double cancer (synchronous double cancer) patients but patients with intramucosal cancer can be enrolled. 3. Stage III to IV and unresectable 4. Planned to undergo chemotherapy (including molecularly-targeted drugs and immune checkpoint inhibitors). 5. Expected survival after enrollment must be >=3 months. 6. Planned to undergo contrast-enhanced thorax and abdomen CT before the cancer treatment or carried out it within 2 months. Planned to undergo contrast-enhanced thorax and abdomen CT for the evaluation of cancer status after starting cancer treatment. 7. Informed consent in writing given freely.
Exclusion criteria
Exclusion criteria: 1. Patients have history of VTE in the past. 2. Patients have recently received radiotherapy except for palliative radiation therapy, chemotherapy and surgery except for minor surgery within the last 4 weeks. 3. Patients using anticoagulant drugs (warfarin, heparin and Direct oral anticoagulants) consistently. 4. Patients have serious renal disease: creatinine clearance<30ml/min, or hypersensitivity to CT contrast media. 5. Patients with active infections. 6. Pregnant or possibly pregnant women. 7. Patients with lower limb amputation. 8. Patients who are inappropriate as a subject of the study judged by the treating physicians or investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objectively confirmed symptomatic or asymptomatic VTE | — |
Secondary
| Measure | Time frame |
|---|---|
| Khorana risk score, Vienna CATS risk score, final values of risk score, final values of biomarkers, amount of change in risk score, amount of change in biomarkers, rate of change in risk score, rate of change in biomarkers, all values of risk score, all values of biomarkers | — |
Countries
Japan
Contacts
Public ContactYohei Harada
Saga University Hospital Division of Hematology and Oncology
Outcome results
None listed